Platelet-activating factor, a critical mediator in the pathogenesis of dextran sulfate sodium-induced colitis in rats

Diseases of the Colon and Rectum

Volumn 46, Issue 1, 2003, Pages 100-110

  Hirayama, Kazuhisa ^a,b   Yokoi, Yoshihiro ^a   Sakaguchi, Takanori ^a   Nakamura, Toshio ^a   Kashiwabara, Hidefumi ^a   Sunayama, Kenichi ^a   Nakamura, Satoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hamamatsu Kita Hospital   (Japan)

Author keywords

Cytokine induced neutrophil chemoattractant; Dextran sulfate sodium induced colitis; Platelet activating factor; Tumor necrosis factor alpha

Indexed keywords

CHEMOTACTIC FACTOR; CYTOKINE; DEXTRAN SULFATE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; ISRAPAFANT; MESSENGER RNA; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; INTESTINE CRYPT; INTESTINE MUCOSA; INTESTINE ULCER; LEUKOCYTE ACTIVATION; MALE; MUCOSAL IMMUNITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NORTHERN BLOTTING; PATHOGENESIS; RAT; TISSUE INJURY; ULCERATIVE COLITIS;

ANALYSIS OF VARIANCE; ANIMALS; COLITIS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INTERLEUKIN-8; MALE; NEUTROPHILS; PLATELET ACTIVATING FACTOR; RATS; RATS, WISTAR; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0037243608     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10350-004-6503-7     Document Type: Article

References (48)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Selby WS, Janossy G, Bofill M, Jewell DP. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation technique. Gut 1984;25:32-40.
3. Toyoda H, Wang SJ, Yang H-J, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-8.
4. Tysk C, Riedesen H, Lindberg E, Panzini B, Podolsky D, Jarnerot G. Colonic glycoproteins in monozygotic twins with inflammatory bowel disease. Gastroenterology 1991;100:419-23.
5. Dohi T, Fujihashi K, Kiyono H, Elson CO, McGhee JR. Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. Gastroenterology 2000;119:724-33.
6. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
7. Roger G, Andes T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-9.
8. Andus T, Taragan SR, Deem R, Toyoda H. Measurement of tumor necrosis factor α mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg Immunol 1993;5:11-7.
9. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin-1 in inflammatory bowel disease: enhanced production during active disease. Gut 1990;31:686-9.
10. Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J Clin Gastroenterol 1995;20:123-6.
11. Daig R, Andus T, Aschenbrenner E, Falk W, Scholmerich J, Gross V, Increased interleukin-8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996;38:216-22.
12. Lotner GZ, Lynch JM, Betz SJ, Henson PM. Human neutrophil-derived platelet activating factor. J Immunol 1980;124:676-84.
13. Chignard M, Lecouedic JP, Tence M, Vargaftig BB, Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature 1979;279:779-800.
14. Hamasaki Y, Mojara M, Saga T, Tai H, Said SI. Platelet-activating factor raises airway and vascular pressure and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis 1984;129:742-6.
15. Tamm M, Bihl M, Eickelberg O, Stulz P, Perruchoud AP, Roth M. Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells. Am J Respir Cell Mol Biol 1998;19:653-61.
16. Guimbaud R, Izzo A, Martinolle JP, et al. Intraluminal excretion of PAF, LysoPAF, and acetylhydrolase in patients with ulcerative colitis. Dig Dis Sci 1995;40:2635-40.
17. Eliakim R, Karmeli F, Razin E, Rachmilewitz D. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology 1988;95: 1167-72.
18. Capasso F, Tavares IA, Bennett A. Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid. Drugs Exp Clin Res 1991;17:351-3.
19. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5.
20. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
21. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994;107:1643-52.
22. Takizawa H, Shintani N, Natsui M, et al. Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. Digestion 1995;56:259-64.
23. Egger B, Carey HV, Procaccino F, et al. Reduced susceptibility of mice overexpressing transforming growth factor α to dextran sodium sulfate induced colitis. Gut 1998;43:64-70.
24. Serizawa A, Nakamura S, Suzuki S, Baba S, Nakano M. Involvement of platelet-activating factor in cytokine production and neutrophil activation after hepatic ischemia-reperfusion. Hepatology 1996;23:1656-63.
25. Sakaguchi T, Nakamura S, Suzuki S, et al. Participation of platelet-activating factor in the lipopolysaccharide-induced liver injury in partially hepatectomized rats. Hepatology 1999;30:959-67.
26. Watanabe K, Konisi K, Fujioka M, Kinoshita S, Nakagawa H. The neutrophil chemoattractant produced by the rat kidney epithelioid cell line NRK-52E is a protein related to the KC/gro protein. J Biol Chem 1989;264:19559-63.
27. Siddiqui RA, Akard LP, Garcia JG, Cui Y, English D. Chemotactic migration triggers IL-8 generation in neutrophilic leukocytes. J Immunol 1999;162:1077-83.
28. O'Flaherty JT, Wykle RL, Miller CH, et al. 1-O-alkyl-sn-glyceryl-3-phosphorycholine: a novel class of neutrophil stimulants. Am J Pathol 1981;103:70-9.
29. Smith JA. Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol 1994;56:672-86.
30. Jaeschke H, Smith CW. Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997;61:647-53.
31. Denault S, April MJ, Stañková J. Transcriptional activation of interleukin-8 gene by platelet-activating factor in human peripheral blood monocytes. Immunology 1997;91:297-302.
32. Bussolino F, Sironi M, Bocchietto E, Mantovani A. Synthesis of platelet-activating factor by polymorphonu-clear neutrophils stimulated with interleukin-8. J Biol Chem 1992;267:14598-603.
33. Kawano Y, Narahara H, Johnston JM. Inhibitory effect of interleukin-8 on the secretion of platelet-activating factor acetylhydrolase by human decidual macrophages. J Soc Gynecol Invest 1999;6:328-32.
34. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993;9:317-43.
35. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
36. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumor necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
37. Cappello M, Keshav S, Prince C, Jewell DP, Gordon S. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridization. Gut 1992;33:1214-9.
38. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35.
39. Sariban E, Imamura K, Luebbers R, Kufe D. Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J Clin Invest 1988;81:1506-10.
40. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989;244:339-43.
41. Han J, Beutler B, Huez G. Complex regulation of tumor necrosis factor mRNA turnover in lipopolysaccharide-activated macrophages. Biochem Biophys Acta 1991;1090:22-8.
42. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-a, interleukin-1β, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
43. Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-α and IFN-γ m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995;46:111-23.
44. Camussi G, Tetta C, Baglioni C. The role of platelet-activating factor in inflammation. Clin Immunol Immunopathol 1990;57:331-8.
45. Wardle TD, Turnberg LA. Potential role for interleukin-1 in the pathophysiology of ulcerative colitis. Clin Sci 1994;86:619-26.
46. Travis SP, Crotty B, Jewell DP. Site of action of platelet-activating factor within the mucosa of rabbit distal colon. Clin Sci 1995;88:51-7.
47. Mahler M, Bristol IJ, Leiter EH, et al. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 1998;274:G544-51.
48. Wang H, Tan X, Chang H, Gonzales-Crussi F, Remick DG, Hsueh W. Regulation of platelet-activating factor receptor gene expression in vivo by endotoxin, platelet-activating factor and endogenous tumour necrosis factor. Biochem J 1997;322:603-8.